Mediamedic/LinkedIn
Oct 4, 2025, 12:30
Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Apr 13, 2026, 06:57Heghine Khachatryan: Why PNH Is More Than a Hemolytic Disease
-
Apr 13, 2026, 05:43Wolfgang Miesbach: A Historic Experiment That Changed Our Understanding of ITP
-
Apr 13, 2026, 04:49Danielle Boyle: This Consultation Is an Opportunity for The Entire ITP Community to Be Heard
-
Apr 13, 2026, 04:18Stephen Cornelissen: You Might Be Eligible to Donate Blood – Here’s Why It’s Worth Checking
-
Apr 13, 2026, 04:12Angie Read: A Powerful Conversation on Survival, Recovery, and Purpose on Stroke Sisters’ Latest Episode
-
Apr 13, 2026, 04:04Ramy Abdelnaby: Telestroke Rounds Show Superior Guideline Adherence in Subacute Care
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management